Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (191-200 of 282) with videos related to

Pageof 29
Sort By:
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Francis Kalemeera, et al.
Plos One|January 23, 2026
Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteersBeth Thompson, Laura J Else, Laura Dickinson, et al.
Antiviral Therapy|August 20, 2003
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokineticsMartina Hennessy, Susan Clarke, J Paul Spiers, et al.
Scientific Reports|August 27, 2017
A first-in-human study of the novel HIV-fusion inhibitor C34-PEG<sub>4</sub>-CholKillian Quinn, Cinzia Traboni, Sujan Dily Penchala, et al.
Drugs in R&D|December 18, 2020
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic ImpairmentFiona Marra, Elise J Smolders, Omar El-Sherif, et al.
Journal of the International AIDS Society|September 19, 2019
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?Lee Fairlie, Catriona Waitt, Shahin Lockman, et al.
Antiviral Research|September 27, 2024
Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK studyDvora Joseph Davey, Sumaya Dadan, Kalisha Bheemraj, et al.
BMJ Open|October 18, 2015
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapySudeep P Pushpakom, Claire Taylor, Ruwanthi Kolamunnage-Dona, et al.
AIDS Research and Therapy|April 2, 2023
Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional studyAllan Buzibye, Kara Wools-Kaloustian, Adeniyi Olagunju, et al.
The Lancet. HIV|September 16, 2024
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort studySam Nightingale, Anna J Dreyer, Kevin G F Thomas, et al.
Pageof 29

Showing results (191-200 of 282) with videos related to

Sort By:
Pageof 29
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Francis Kalemeera, et al.
Plos One|January 23, 2026
Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteersBeth Thompson, Laura J Else, Laura Dickinson, et al.
Antiviral Therapy|August 20, 2003
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokineticsMartina Hennessy, Susan Clarke, J Paul Spiers, et al.
Scientific Reports|August 27, 2017
A first-in-human study of the novel HIV-fusion inhibitor C34-PEG<sub>4</sub>-CholKillian Quinn, Cinzia Traboni, Sujan Dily Penchala, et al.
Drugs in R&D|December 18, 2020
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic ImpairmentFiona Marra, Elise J Smolders, Omar El-Sherif, et al.
Journal of the International AIDS Society|September 19, 2019
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?Lee Fairlie, Catriona Waitt, Shahin Lockman, et al.
Antiviral Research|September 27, 2024
Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK studyDvora Joseph Davey, Sumaya Dadan, Kalisha Bheemraj, et al.
BMJ Open|October 18, 2015
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapySudeep P Pushpakom, Claire Taylor, Ruwanthi Kolamunnage-Dona, et al.
AIDS Research and Therapy|April 2, 2023
Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional studyAllan Buzibye, Kara Wools-Kaloustian, Adeniyi Olagunju, et al.
The Lancet. HIV|September 16, 2024
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort studySam Nightingale, Anna J Dreyer, Kevin G F Thomas, et al.
Pageof 29